The Optimization Of The Procedure For The Synthesis Of Gefitinib

Gefitinib is a small molecule Anilinoquinazoline compound which is a selective tyrosine kinase inhibitor. It is a novel targeted anticancer drug for the treatment of non-small cell lung cancer. Targeted drugs combine with chemotherapy drugs effectively will give patients greater benefits. Gefitinib which is the first choice for the current clinical application occupies a total market share in the global anti-cancer drugs.In this thesis, we optimized the synthetic route of gefitinib after researching the literatures and give the product in42%overall yield via seven steps (increasing29percent compared to the13%overall yield of literature reported), which provide an improved method with lower cost for industry.